Trial Profile
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Alemtuzumab (Campath)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Large granular lymphocytic leukaemia
- Focus Therapeutic Use
- 09 Mar 2021 Status changed from active, no longer recruiting to completed.
- 09 Mar 2021 Status changed from active, no longer recruiting to completed.
- 03 Oct 2018 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.